Halozyme views its drug delivery technology for biologic medicines as complementary to Evotec’s biologic drug manufacturing capabilities. But according to Halozyme, Evotec was unwilling to engage in any merger discussions.
Halozyme’s offer comes as Evotec deals with several business setbacks and a languishing stock price. Earlier this year, Evotec implemented a cost-saving corporate restructuring.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Demand for alternative drug delivery methods has the potential to reshape therapeutic markets and improve clinical outcomes. New innovations, especially oral alternatives, are poised to drive broad changes across the entire sector.
Surge Therapeutics' hydrogel is engineered to deliver a cancer immunotherapy. Rather than replace surgery, CEO Michael Goldberg says the hydrogel could supplement this standard of care for solid tumors. The startup's Series A financing will support the technology's first test in humans.
Vector BioPharma has launched from the biotech startup incubator of Versant Ventures, which is backing the company with a $30 million Series A financing. Vector is developing virus-like particles with the capability to deliver large payloads of genetic medicines to a wide range of tissues.
By adding adherence and connectivity capabilities to home-based solutions, clinicians can maintain open lines of communication with patients, helping patients better care for themselves from the comfort of their homes.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
In less than one year, ReCode Therapeutics has reeled in $200 million in financing. Big pharmaceutical companies are taking notice of the biotech startup’s technology, which enables lipid nanoparticles to go a wide range of organs and tissues, potentially broadening the reach of genetic medicines.
Regulatory setbacks for a new migraine treatment have led Zosano Pharma to restructure, laying off about 31% of its staff. Zosano is one of several biotechs that announced cost-saving measures this week.
The time is ripe for wide adoption of wearable drug delivery devices as more patients seek home care in a lower-cost setting and because these devices are able to deliver complex, highly viscose drugs currently being developed.
Company raises $5 million from Lagunita Biosciences for technology to improve eye drug administration.
Executives from Imagine360, Verily, BrightInsight, Lantern, and Rhapsody shared their approaches to reducing healthcare costs and facilitating digital transformation.
Drug delivery may not mean swallowing a pill or getting a shot anymore. From dissolvable wafers to micro-robots, drug delivery is changing for the better.
MedCity News has partnered with BioCrossroads to provide coverage focused on Indiana’s next generation of growth and innovation in life sciences Purdue University spinout Biokorf is developing a new way to manufacture pharmaceuticals, attempting to personalize drug dosage and delivery methods. It’s certainly an interesting endeavor in this era of precision medicine. Chief Scientific Officer Rodolfo Pinal put the use-case […]